Update: ImmunityBio (IBRX) Delivers a Trifecta of News. The Valley of Death is Filling Up with Revenue.
$113M in revenue, a potential First-Line Killer App in bladder cancer, and a cell therapy proof-of-concept. The bear case just got harder to defend.
Immunitybio (IBRX) has had quite the busy week - stay caught up with all of my updates HERE and HERE, and check out my original deep dive HERE.
The News Cycle
Between January 15 and 16, 2026, ImmunityBio (IBRX) released three more press releases that fundamentally alter the company’s risk profile.
The Commercial Receipt: Preliminary 2025 Net Product Revenue hit $113 Million — a 700% year-over-year increase.
The Clinical Killer App: Interim Phase 3 data in BCG-Naïve (First-Line) Bladder Cancer showed ANKTIVA + BCG achieving an 84% Complete Response (CR) rate vs. 52% for BCG alone.
The Scientific Cherry on Top: A case study of a durable (15-month) Complete Response (CR) in Waldenstrom Macroglobulinemia using their chemotherapy-free CD19 CAR-NK cell therapy.
The Take
If you’ve been following my posts this week, you’ll recall that a core risk has been the Dilution Gap — the cash burn required to bridge the company to its next major regulatory win.
This week’s news implies that bridge is largely built.
1. The Financial Reality Check: $113M Revenue
The Math: Through Q3 2025, the company had reported ~$74.7M in revenue. A full-year total of $113M implies Q4 2025 revenue of ~$38.3M.
The Trend: This represents ~20% sequential growth over Q3 ($31.8M).
The Implication: With a quarterly operating cash burn of ~$78M (based on Q3 YTD data), generating ~$38M in quarterly revenue means the commercial engine is now covering roughly half of the company’s operating burn.
Verdict: The company isn’t self-sustaining yet, but it no longer appears to be a cash incinerator. It is a revenue-generating commercial biotech. The Saudi Card (potential non-dilutive funding) combined with this revenue stream makes a desperate equity raise significantly less likely.
2. The Killer App: First-Line Bladder Cancer
This is arguably the most significant clinical update since the original FDA approval.
The Context: ANKTIVA is currently approved for BCG-unresponsive disease (a salvage setting). Moving into BCG-Naïve (First-Line) could expand the Total Addressable Market (TAM) by 3-4x.
The Interim Phase 3 Data: In an FDA-requested interim analysis (n=43), ANKTIVA + BCG showed an 84% Complete Response (CR) compared to 52% for BCG alone.
The Moat: The standard of care (BCG monotherapy) fails in ~30-40% of patients. Beating it by 32 percentage points (84% vs 52%) is a massive efficacy signal. If this holds up in the full data set, ANKTIVA could become the new Standard of Care for all high-risk NMIBC patients, not just the refractory ones.
3. The Science Project: Cell Therapy (CAR-NK)
The Data Update: A single patient with Waldenstrom Macroglobulinemia (a rare lymphoma) achieved a Complete Response lasting 15+ months using CD19 t-haNK (off-the-shelf CAR-NK cells) without chemotherapy.
The Reality: n=1. This is just a case study.
The Value: While probably not a major driver for the stock price today, this serves as proof of biology for the third corner of ImmunityBio’s platform (Cell Therapy). It demonstrates their cryopreserved NK cells can actually kill tumor cells in a human without the toxic conditioning chemotherapy required by competitors like CAR-T.
Updated Verdict
Status: BUY (High Conviction)
The Thesis Shift:
We have moved from show me to scale me.
Commercial De-Risking: Revenue is real ($113M) and growing. The J-Code (9028) is accelerating uptake.
Pipeline Expansion: The First-Line bladder cancer data (84% CR) suggests a clear path to a blockbuster TAM.
Global Arbitrage: The Saudi approval (Lung Cancer) and U.S. data (Bladder) create multiple shots on goal.
The Remaining Risk:
The FDA’s refuse to file on the papillary indication (from May 2025) is still an open loop. The company needs to clarify if the new first-line data creates a workaround or if they still need to run a separate randomized trial for papillary disease. But with revenue ramping and first-line data looking this strong, the company seems to have leverage it didn’t have six months ago.
Disclaimer: This is not financial advice. Interim data is subject to change in final analysis. Do your own diligence.